Two radiation approaches for advanced nasopharynx cancer after initial treatment

This trial is testing whether a smarter way to deliver radiation therapy can work just as well as standard radiation for advanced nasopharynx cancer. After you receive initial chemotherapy combined with an immunotherapy medication (a PD-1/PD-L1 inhibitor), you would be randomly assigned to receive either standard radiation therapy or a newer approach that uses PET-CT scans to reduce radiation dose to areas where the tumor has already died, while maintaining full dose to areas still fighting the disease. Both groups also receive chemotherapy alongside radiation.

Standard radiation therapy treats the entire tumor area equally, which can cause side effects in healthy tissue. This trial is exploring whether personalizing the radiation dose based on which parts of the tumor are still active—shown on metabolic imaging—can reduce harm while keeping the treatment effective.